- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Systemic lupus erythematosus
- Meeting Date: July 2022
- Public Summary Document (PSD) July 2022 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) July 2022 PBAC Meeting - (Word 324KB)
Anifrolumab – July 2022
Anifrolumab: Solution concentrate for I.V. infusion 300 mg in 2 mL; Saphnelo®
Last updated
11 November 2022